What development phase is Multiple cardiovascular drugs related to "Golden Triangle" in?

Multiple cardiovascular drugs related to "Golden Triangle" is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Multiple cardiovascular drugs related to "Golden Triangle"

Sun Yat-sen University · FDA-approved active Small molecule Quality 10/100

Sun Yat-sen University markets a suite of cardiovascular drugs under the "Golden Triangle" brand, which is currently available on the market for the prevention of infection in minor cuts, scrapes, and burns. A key strength is the protection afforded by a key composition patent, which is set to expire in 2028. The primary risk lies in the potential increase in competition following the patent expiry, which could impact market share and revenue.

At a glance

Generic name	Multiple cardiovascular drugs related to "Golden Triangle"
Sponsor	Sun Yat-sen University
Drug class	Antiseptic [EPC]
Modality	Small molecule
Phase	FDA-approved

Approved indications

Prevention of infection in minor cuts, scrapes, burns

Common side effects

No common side effects on file.

Key clinical trials

Early Specialized Cardiovascular Intervention Based on Impedance Cardiography in Locally Advanced Non-small Cell Lung Cancer Patients (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results